FDA Approves Vosoritide for Children With Achondroplasia : v

Injection improves growth in children aged 5 years and older with the most common form of dwarfism.

Related Keywords

United States , Theresa Kehoe , Lynda Polgreen , Drug Administration , General Endocrinology , Drug Evaluation , Achondroplasia , Children , Child , Childhood , Ediatrics , Kids , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Short Stature , Endocrinology , Ndocrine System , Diabetes Mellitus , Bones , Insulin Analog , Insulin Analogue , Minerals , Vomiting , Grant , Adverse Effects , Side Effects , Biologic Therapy , Birth , , Europe , European , Genetic Disorder , Impairment , Targeted Therapy , Washington , Ewas ,